May 24, 2023
GeneDx to Participate in Upcoming Investor Conferences in June
May 23, 2023
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
May 22, 2023
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 9, 2023
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
May 4, 2023
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
May 3, 2023
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
April 28, 2023
GeneDx Announces Reverse Stock Split
April 18, 2023
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
April 3, 2023
GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel
March 20, 2023
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
Displaying 1 - 10 of 21